author：Tyden, Gunnar ; Donauer, Johannes 2; Wadstrom, Jonas 3; Kumlien, Gunilla 1; Wilpert, Jochen 2; Nilsson, Thomas 3; Genberg, Helena 1; Pisarski, Przemislaw 2; Tufveson, Gunnar
source：Transplantation. 83(9):1153-1155, May 15, 2007.
abstract：Background. A new protocol for ABO-incompatible kidney transplantation has recently been introduced. We report here on the joint experience of the implementation in Stockholm and Uppsala, Sweden and Freiburg, Germany.
Methods. The new protocol utilizes antigen-specific immunoadsorption to remove existing ABO-antibodies, rituximab, and intravenous immunoglobulin to prevent the rebound of antibodies, and conventional tacrolimus, mycophenolate-mofetil, and prednisolone immunosuppression. Sixty consecutive ABO-incompatible kidney transplantations were included in the study. The outcome is compared with the results of 274 ABO-compatible live donor transplantations performed during the same period.
Results. Two of the ABO-incompatible grafts have been lost (non-compliance and death with functioning graft). All the remaining 58 grafts had good renal function at a follow-up of up to 61 months. We did not observe any late rebound of antibodies and there were no humoral rejections. Graft survival was 97% for the ABO-incompatible compared with 95% for the ABO-compatible. Patient survival was 98% in both groups. There was a significant variation in preoperative A/B-antibody titer between the centers, with a median 1:8 in Uppsala, median 1:32 in Stockholm and median 1:128 in Freiburg. More preoperative antibody adsorptions were therefore needed in Freiburg than in Stockholm and Uppsala.
Conclusions. The new protocol was easily implemented and there were no graft losses that could be related to ABO-incompatibility. A significant inter-institutional variation in the measurement of anti-AB-antibodies was found, having a substantial impact on the number of immunoadsorptions and consequently on the total cost for the procedure. A standardized fluorescence-activated cell sorting technique for antibody quantification is much needed.
本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领
title：Implementation of a Protocol for ABO-Incompatible Kidney Transplantation - A Three-Center Experience With 60 Consecutive Transplantations.
标题：ABO血型不合的肾移植实施方案――3个中心连续60例的移植经验
author：Tyden, Gunnar ; Donauer, Johannes 2; Wadstrom, Jonas 3; Kumlien, Gunilla 1; Wilpert, Jochen 2; Nilsson, Thomas 3; Genberg, Helena 1; Pisarski, Przemislaw 2; Tufveson, Gunnar
作者：Tyden, Gunnar ; Donauer, Johannes 2; Wadstrom, Jonas 3; Kumlien, Gunilla 1; Wilpert, Jochen 2; Nilsson, Thomas 3; Genberg, Helena 1; Pisarski, Przemislaw 2; Tufveson, Gunna
source：Transplantation. 83(9):1153-1155, May 15, 2007.
源自：《器官移植》。2007年5月15日，83(9)：1153-1155。
abstract：Background. A new protocol for ABO-incompatible kidney transplantation has recently been introduced. We report here on the joint experience of the implementation in Stockholm and Uppsala, Sweden and Freiburg, Germany.
摘要：背景. 一项关于ABO血型不合的肾移植的新方案近来被推出。我们的报告是据在瑞典的斯德哥尔摩和乌普撒拉以及德国的浮雷堡实施经验得出。
Methods. The new protocol utilizes antigen-specific immunoadsorption to remove existing ABO-antibodies, rituximab, and intravenous immunoglobulin to prevent the rebound of antibodies, and conventional tacrolimus, mycophenolate-mofetil, and prednisolone immunosuppression. Sixty consecutive ABO-incompatible kidney transplantations were included in the study. The outcome is compared with the results of 274 ABO-compatible live donor transplantations performed during the same period.
方法：新方案利用抗原特异性免疫吸附，清除现有的ABO血型抗体，利妥昔单抗与静脉注射免疫球蛋白防止抗体复原，以及常规的他克莫司，麦考酚酸莫酯和泼尼松龙免疫抑制剂。在该研究中有60例相连的ABO血型不合肾移植患者。结果与同时期274例 ABO血型适合的活体移植手术做对比。
Results. Two of the ABO-incompatible grafts have been lost (non-compliance and death with functioning graft). All the remaining 58 grafts had good renal function at a follow-up of up to 61 months. We did not observe any late rebound of antibodies and there were no humoral rejections. Graft survival was 97% for the ABO-incompatible compared with 95% for the ABO-compatible. Patient survival was 98% in both groups. There was a significant variation in preoperative A/B-antibody titer between the centers, with a median 1:8 in Uppsala, median 1:32 in Stockholm and median 1:128 in Freiburg. More preoperative antibody adsorptions were therefore needed in Freiburg than in Stockholm and Uppsala.
结果：两例ABO血型不合的移植体失败(不匹配功能性移植后死亡)。随访所有剩余的具有良好肾功能的58例移植者，后续长达61个月。我们没有看到任何在移植后的抗体复原和体液排斥反应。ABO血型不合对比ABO血型适合的成活率达97%比95%。在两组汇总病人的存活率为98% 。在三个测试中心间，两组在术前A/B抗体滴度上有显着差异，乌普萨拉中位数1:8，斯德哥尔摩中位数1:32和浮雷堡中位数1:128。因此，浮雷堡比斯德哥尔摩和乌普萨拉需要更多的术前抗体吸附。
Conclusions. The new protocol was easily implemented and there were no graft losses that could be related to ABO-incompatibility. A significant inter-institutional variation in the measurement of anti-AB-antibodies was found, having a substantial impact on the number of immunoadsorptions and consequently on the total cost for the procedure. A standardized fluorescence-activated cell sorting technique for antibody quantification is much needed.
结论：新方案实施容易，也没有与ＡＢＯ血型不合相关的移植体的丢失。在抗AB抗体治疗方法上，一个显著的交互跨体制变化被发现，这将会对免疫吸附数量和操作总成本有重大影响的。标准化荧光激活细胞分选技术用于抗体定量是十分必要的。
编译后：约 634个字
Tyden, Gunnar等研究者根据在瑞典斯德哥尔摩和乌普撒拉以及德国浮雷堡三个中心ABO血型不合的肾移植实施经验，提出了一项关于ABO血型不合的肾移植的新方案。该研究发表在2007年5月15日，《器官移植》83(9)：1153-1155
新方案利用抗原特异性免疫吸附，清除现有的ABO血型抗体，利妥昔单抗与静脉注射免疫球蛋白防止抗体复原，以及常规的他克莫司，麦考酚酸莫酯和泼尼松龙免疫抑制剂。在该研究中有60例相连的ABO血型不合肾移植患者。结果与同时期274例 ABO血型适合的活体移植手术做对比。
结果显示如下：两例ABO血型不合的移植提已经失败(不匹配功能性移植后死亡)。随访所有剩余的具有良好肾功能的58例移植者，后续长达61个月。我们没有看到任何在移植后的抗体复原和体液排斥反应。ABO血型不合对比ABO血型适合的成活率达97%比95%。在两组汇总病人的存活率为98% 。在三个测试中心间，两组在术前A/B抗体滴度上有显着差异，乌普萨拉中位数1:8，斯德哥尔摩中位数1:32和浮雷堡中位数1:128。因此，浮雷堡比斯德哥尔摩和乌普萨拉需要更多的术前抗体吸附。
根据上述结果，研究者提出：新方案实施容易，且没有因ＡＢＯ血型不合而造成移植体损失。在抗AB抗体的测量上,发现存在显著的研究机构内差异,这对免疫吸附的数量,及由此对移植过程的总成本将会产生重要影响。
该文章的最后一段，A significant inter-institutional variation in the measurement of anti-AB-antibodies was found, having a substantial impact on the number of immunoadsorptions and consequently on the total cost for the procedure.. 个人觉得翻译不好，敬请战友指正！
问一下，ABO血型不合，到底符合输血原则不？
60例里面有多少是绝对不合输血原则的？
A significant inter-institutional variation in the measurement of anti-AB-antibodies was found, having a substantial impact on the number of immunoadsorptions and consequently on the total cost for the procedure..
在抗AB抗体的测量上,发现存在显著的研究机构内差异,这对免疫吸附的数量,和由此对移植过程的总成本都产生重要影响.
由于中间有个consequently表示因果关系,但是又不想增加篇幅,所以翻译的有点拗口,不知是否合理?
或者去掉后改成:
在抗AB抗体的测量上,发现存在显著的研究机构内差异,这对免疫吸附的数量和移植过程的总成本都产生重要影响.
title：Implementation of a Protocol for ABO-Incompatible Kidney Transplantation - A Three-Center Experience With 60 Consecutive Transplantations.
标题：ABO血型不合的肾移植实施方案――3个中心连续60例的移植经验
author：Tyden, Gunnar ; Donauer, Johannes 2; Wadstrom, Jonas 3; Kumlien, Gunilla 1; Wilpert, Jochen 2; Nilsson, Thomas 3; Genberg, Helena 1; Pisarski, Przemislaw 2; Tufveson, Gunnar
作者：Tyden, Gunnar ; Donauer, Johannes 2; Wadstrom, Jonas 3; Kumlien, Gunilla 1; Wilpert, Jochen 2; Nilsson, Thomas 3; Genberg, Helena 1; Pisarski, Przemislaw 2; Tufveson, Gunna
source：Transplantation. 83(9):1153-1155, May 15, 2007.
源自：《器官移植》。2007年5月15日，83(9)：1153-1155。
abstract：Background. A new protocol for ABO-incompatible kidney transplantation has recently been introduced. We report here on the joint experience of the implementation in Stockholm and Uppsala, Sweden and Freiburg, Germany.
摘要：背景．近来已推出一项新的ＡＢＯ血型不合肾移植实施方案．我们就瑞典的斯德哥尔摩和乌普撒拉以及德国的浮雷堡共同的实施经验做出报告。
Methods. The new protocol utilizes antigen-specific immunoadsorption to remove existing ABO-antibodies, rituximab, and intravenous immunoglobulin to prevent the rebound of antibodies, and conventional tacrolimus, mycophenolate-mofetil, and prednisolone immunosuppression. Sixty consecutive ABO-incompatible kidney transplantations were included in the study. The outcome is compared with the results of 274 ABO-compatible live donor transplantations performed during the same period.
方法：新方案利用抗原特异性免疫吸附剂清除存在的ABO血型抗体，使用利妥昔单抗和静脉注射免疫球蛋白防止抗体反弹，并且常规使用他克莫司，麦考酚酸吗乙酯和泼尼松龙等免疫抑制剂。该研究包括６０例连续实施ＡＢＯ血型不合肾移植患者。该研究结果与同时期274例 ABO血型相合的活体移植结果做对比。
Results. Two of the ABO-incompatible grafts have been lost (non-compliance and death with functioning graft). All the remaining 58 grafts had good renal function at a follow-up of up to 61 months. We did not observe any late rebound of antibodies and there were no humoral rejections. Graft survival was 97% for the ABO-incompatible compared with 95% for the ABO-compatible. Patient survival was 98% in both groups. There was a significant variation in preoperative A/B-antibody titer between the centers, with a median 1:8 in Uppsala, median 1:32 in Stockholm and median 1:128 in Freiburg. More preoperative antibody adsorptions were therefore needed in Freiburg than in Stockholm and Uppsala.
结果：两例ABO血型不合的移植体失败(不匹配和功能性移植物死亡)。在长达六个月的随访中，剩余的５８例移植体功能良好。我们没有观察到移植后的抗体反弹和体液排斥反应。ABO血型不合与ABO血型相合的移植物成活率相比，前者是９７％，后者是９５％。两组病人的存活率都是98% 。三个研究中心的术前A/B抗体滴度有显着差异，乌普萨拉中位数1:8，斯德哥尔摩中位数1:32和浮雷堡中位数1:128。因此，浮雷堡中心比其他两个中心术前需要更多的抗体吸附剂。
Conclusions. The new protocol was easily implemented and there were no graft losses that could be related to ABO-incompatibility. A significant inter-institutional variation in the measurement of anti-AB-antibodies was found, having a substantial impact on the number of immunoadsorptions and consequently on the total cost for the procedure. A standardized fluorescence-activated cell sorting technique for antibody quantification is much needed.
结论：新方案实施容易，也没有与ＡＢＯ血型不合相关的移植体的丢失。在三个研究中心之间，我们发现抗AB抗体的测量方法明显不同，这会对免疫吸附剂的剂量和手术总成本产生巨大影响。因此，非常有必要使用标准化荧光激活细胞分类术进行抗体量化测定。
The new protocol was easily implemented and there were no graft losses that could be related to ABO-incompatibility
新方案实施容易，也没有与ＡＢＯ血型不合相关的移植体的丢失。
新方案实施容易，也没有因ＡＢＯ血型不合而造成移植物丢失．
这句究竟怎样译妥当就有劳各位朋友了．
The new protocol was easily implemented and there were no graft losses that could be related to ABO-incompatibility
个人觉得第二种合理些,不知graft losses 翻译成"移植失败"是否更合理?
新方案实施容易，也没有因ＡＢＯ血型不合而造成移植物失败．
谢谢各位热心战友！
看翻译，容易懂
同意楼上说法
explorerqsb战友的翻译更到位一些，graft loss 一般翻译为“移植物丢失”，一般为非手术的因素导致“移植失败”，也包括带功能的移植物丢失，比如车祸导致宿主死亡，但死亡时移植物功能可以正常。
The new protocol was easily implemented and there were no graft losses that could be related to ABO-incompatibility
新方案实施容易，也没有与ＡＢＯ血型不合相关的移植体的丢失。同意这种译法。